| Identification | Back Directory | [Name]
Pelidotin | [CAS]
1438849-92-3 | [Synonyms]
Pelidotin
MC-VC-PABC-Aur0101
L-Valinamide, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-2-methylalanyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[... | [Molecular Formula]
C68H100N12O14S | [MDL Number]
MFCD32201145 | [MOL File]
1438849-92-3.mol | [Molecular Weight]
1341.68 |
| Chemical Properties | Back Directory | [Boiling point ]
1380.8±65.0 °C(Predicted) | [density ]
1.222±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
10.56±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
MC-VC-PABC-Aur0101 is a agent-linker conjugate for ADC with potent antitumor activity by using Aur0101 (an auristatin microtubule inhibitor), linked via the ADC linker MC-VC-PABC. | [IC 50]
Auristatin | [References]
[1] Samantha Congreve, et al. Antibody drug conjugates (ADC) Current status and mapping of ADC:s in clinical programs. |
|
|